Rafferty Asset Management, LLC Iveric Bio, Inc. Transaction History

Rafferty Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$26.24 - $39.63 $2.56 Million - $3.87 Million	-97,540 Reduced 30.92%	217,928 $8.57 Million
Q1 2023 May 11, 2023	SELL	$18.67 - $24.56 $1.55 Million - $2.04 Million	-82,888 Reduced 20.81%	315,468 $7.68 Million
Q4 2022 Feb 13, 2023	BUY	$17.24 - $23.95 $441,240 - $612,976	25,594 Added 6.87%	398,356 $8.53 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $208,172 - $411,694	22,146 Added 6.32%	372,762 $6.69 Million
Q2 2022 Aug 12, 2022	BUY	$9.12 - $18.9 $221,634 - $459,307	24,302 Added 7.45%	350,616 $3.37 Million
Q1 2022 May 13, 2022	SELL	$12.15 - $16.83 $426,647 - $590,985	-35,115 Reduced 9.72%	326,314 $5.49 Million
Q4 2021 Feb 10, 2022	BUY	$13.83 - $18.78 $2.63 Million - $3.58 Million	190,515 Added 111.47%	361,429 $6.04 Million
Q3 2021 Nov 10, 2021	BUY	$7.07 - $17.5 $534,089 - $1.32 Million	75,543 Added 79.21%	170,914 $2.78 Million
Q2 2021 Aug 10, 2021	SELL	$5.69 - $7.17 $354,464 - $446,662	-62,296 Reduced 39.51%	95,371 $602,000
Q1 2021 May 10, 2021	BUY	$5.08 - $6.89 $648,096 - $879,012	127,578 Added 424.0%	157,667 $974,000
Q4 2020 Feb 10, 2021	BUY	$5.65 - $7.66 $170,002 - $230,481	30,089 New	30,089 $208,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.